# IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

> **NCT02697292** · PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 17 (actual)

## Conditions studied

- Autoimmune Epilepsy

## Interventions

- **DRUG:** Intravenous Immunoglobulin
- **DRUG:** Placebos
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02697292
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2018-12-03
- **Final completion:** 2018-12-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-12-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697292, "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02697292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*